Jenny Y. Gan

Jenny Y. Gan

Auto-generated profile, based on publicly available information

Jenny Y. Gan

Harvard Medical School, Mass General Brigham, 55 Fruit Street, Boston, MA, 02114, United States, 1-617-726-2000

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2022 in Transcultural Psychiatry
Verified
Journal Article
Closed access
MRMicaela Rodriguez
Micaela Rodriguez
TOTom L. Osborn
Tom L. Osborn
JGJenny Y. Gan
Jenny Y. Gan
JWJohn R. Weisz
John R. Weisz
BBBenjamin W. Bellet
Benjamin W. Bellet
Loneliness is associated with negative mental health outcomes and is particularly common among adolescents. Yet, little is known about the dynamics of adolescent loneliness in non-Western, low-income nations. Accordingly, we estimated the severity of loneliness in a sample of Kenyan adolescents and used mixed-effects regression modelling to determine the socio-cultural factors associated with loneliness. We also used network analysis to examine the associations between loneliness, depression, and anxiety at the symptom level. We analyzed data from a large sample (N = 2,192) of school-attending Kenyan adolescents aged 12–19 (58.3% female, 41.7% male). Standardized measures of loneliness (ULS-8), depression (PHQ-8), and anxiety (GAD-7) were used. Our mixed-effects model revealed that female and lower-income adolescents felt lonelier. The perception of feeling alone emerged as the aspect of loneliness most strongly linked to depression and anxiety symptoms. Our findings establish an estimate of loneliness levels in Kenyan adolescents, and identify possible socio-cultural factors associated with loneliness. We found that perceptions of isolation more strongly linked loneliness to psychopathology than did objective measures of isolation or preferences for social contact. Finally, we identify specific aspects of loneliness that could prove to be treatment targets for youth psychopathology; however, further research is needed. Limitations, future directions, and clinical implications are discussed.

30 October 2024 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
XDXinyi Ding
Xinyi Ding
FRFrancesco Romano
Francesco Romano
Itika GargItika Garg
Itika Garg
JGJenny Gan
Jenny Gan
FVFilippos Vingopoulos
Filippos Vingopoulos
JMJoan Miller
Joan Miller

19 August 2025 in Ophthalmology Retina
Verified
Journal Article
Closed access
XDXinyi Ding Ding
Xinyi Ding Ding
JXJia Xu
Jia Xu
FRFrancesco Romano
Francesco Romano
Itika GargItika Garg
Itika Garg
JGJenny Gan
Jenny Gan
JMJoan Miller
Joan Miller

1 January 2025 in Case Reports in Ophthalmological Medicine
Verified
Journal Article
Open access
JGJenny Y. Gan
Jenny Y. Gan
MLMichael Lin
Michael Lin
This report highlights the first known report of an intraocular eyelash embedded in the inferior midperipheral iris following a routine cataract surgery. A 74‐year‐old female presented 5 months postoperatively from a full‐thickness macular hole repair with a 3+ nuclear sclerotic cataract. She underwent an uneventful left eye cataract extraction with insertion of posterior chamber intraocular lens (PCIOL). Review of surgical video revealed well‐draped eyelashes and no introduction of an eyelash into the anterior chamber at any point during surgery. The first postoperative visit was notable for no foreign bodies and centered PCIOL. Then, 1 week postoperatively, the anterior segment examination revealed a linear foreign body embedded in the inferior midperipheral iris, without corneal endothelium touch. The foreign body was removed in the operating room and revealed to be an eyelash by pathology. The patient’s visual acuity during her first two postoperative visits was 20/30 and improved to 20/20 with refraction at her 1‐month postoperative visit. There was minimal postoperative inflammation and no evidence of endophthalmitis. To prevent introduction of an intraocular eyelash associated with cataract surgery, appropriate measures intraoperatively and postoperatively should be taken, including meticulous draping of the eyelashes and lids, diligent corneal wound hydration, and clear patient education.

23 July 2026 in JMIR Research Protocols
Verified
Journal Article
Open access
EMElizabeth N Madva
Elizabeth N Madva
JHJeff C Huffman
Jeff C Huffman
HBHelen Burton-Murray
Helen Burton-Murray
EMEmmett McGranaghan
Emmett McGranaghan
MBMegan Bidgood
Megan Bidgood
CCChristopher M Celano
Christopher M Celano
Background: There is a critical need for acceptable, scalable, and mechanistically targeted behavioral health interventions for irritable bowel syndrome (IBS), known as brain-gut behavior therapies (BGBTs). Although positive psychology (PP) interventions, which focus on the cultivation of positive psychological well-being, have been linked to improved health outcomes across diverse medical populations, they have not yet been investigated in IBS. To address this gap, we developed WISH (Well-Being in IBS: Strengths and Happiness), a novel, 9-week, phone-delivered PP-based BGBT for individuals with IBS. Objective: This randomized controlled trial (RCT) aims to evaluate the feasibility, acceptability, preliminary effects, and candidate gut-brain mechanisms of a 9-week phone-delivered PP intervention for IBS compared with a time- and attention-matched educational control. Methods: The WISH 2.0 trial is a parallel-group, 9-week pilot RCT that aims to enroll 50 adults meeting Rome IV criteria for IBS. Participants are randomized (1:1), stratified by IBS subtype and gender, to either the WISH 2.0 intervention or an educational control condition. Both conditions consist of 9 weekly 30-minute phone sessions accompanied by weekly manualized exercises. Primary outcomes are feasibility (proportion completing ≥6 of 9 sessions) and acceptability (weekly ease and utility ratings). Secondary outcomes include WISH 2.0’s preliminary effects on health-related, health behavior, and psychological outcomes, assessed at 4 time points: baseline, intervention midpoint, the postintervention assessment, and the 3-month postintervention assessment. Candidate gut-brain mechanisms that might underlie WISH 2.0’s effects, including changes in autonomic function (heart rate variability), interoception (self-report measure), gene expression (whole transcriptome RNA sequencing), and immune system activity (serum inflammatory biomarkers), will be explored before and after the intervention. Results: The trial was approved by the Mass General Brigham Institutional Review Board and prospectively registered at ClinicalTrials.gov in March 2025. Funding was awarded in June 2025. Following a study start-up period, recruitment commenced in October 2025 and is ongoing. As of July 2026, 20 participants have been enrolled. Study completion is anticipated in August 2028. Conclusions: This trial will determine the feasibility and acceptability of WISH 2.0, a novel PP intervention for IBS. Comparative results between WISH 2.0 and an educational control, including the possibility of equivalent outcomes, will provide important mechanistic insights and facilitate further optimization of BGBTs for IBS, informing a future fully powered efficacy trial.